Document:

EX-10.9

 Exhibit 10.9 

NON-DISCLOSURE, DEVELOPMENTS AND NON-COMPETITION 

AGREEMENT 
 In
consideration and as a condition of my service in the capacity of an employee, officer, director or consultant (“Business Relationship”) to Mevion Medical Systems Incorporated, and any of its subsidiaries, divisions or affiliates (the
“Company”), I hereby agree as follows: 
 1. Best Efforts. During the period of my Business Relationship with the Company, I
shall devote my full time and best efforts to the business of the Company, and I shall neither pursue any business opportunity outside the Company nor take any position with any organization other than the Company without the written approval of the
President or his/her designee. 
 2. Nondisclosure. I shall not at any time, whether during or after the termination of my Business
Relationship, reveal to any person or entity any Confidential Information except to employees of the Company who need to know such Confidential Information for the purposes of their employment, or as otherwise authorized by the Company in writing.
The term “Confidential Information” shall include any information concerning the organization, business or finances of the Company or of any third party which the Company is under an obligation to keep confidential that is maintained by
the Company as confidential. Such Confidential Information shall include, but is not limited to, trade secrets or confidential information respecting products in development, inventions, products, designs, methods, know-how, techniques, systems,
processes, specifications, blueprints, software programs, works of authorship, content, customer lists, customer information, financial information, pricing information, personnel information, business plans, projects, plans and proposals. I shall
keep confidential all matters entrusted to me and shall not use or attempt to use any Confidential Information except as may be required in the ordinary course of performing my duties as an employee of the Company, nor shall I use any Confidential
Information in any manner which may injure or cause loss or may be calculated to injure or cause loss to the Company, whether directly or indirectly. 

3. Company Property. I agree that during my Business Relationship I shall not make, use or permit to be used any Company Property
otherwise than for the benefit of the Company. The term “Company Property” shall include all notes, memoranda, reports, lists, records, drawings, sketches, specifications, software programs, software code, data, computers, cellular
telephones, pagers, credit and/or calling cards, keys, access cards, documentation or other materials of any nature and in any form, whether written, printed, electronic or in digital format or otherwise, relating to any matter within the scope of
the business of the Company or concerning any of its dealings or affairs and any other Company property in my possession, custody or control. I further agree that I shall not, after the termination of my Business Relationship, use or permit others
to use any such Company Property. I acknowledge and agree that all Company Property shall be and remain the sole and exclusive property of the Company. Immediately upon the termination of my Business Relationship I shall deliver all Company Property
in my possession, and all copies thereof, to the Company. 

 4. Assignment of Developments. 

(a) If at any time or times during my Business Relationship, I shall (either alone or with others) make, conceive, create, discover, invent or
reduce to practice any Development that (i) relates to the business of the Company or any partner or sponsor of the Company or any of the products or services being developed, manufactured, licensed or sold by the Company or which may be used
in relation therewith; or (ii) results from tasks assigned to me by the Company; or (iii) results from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company, then all such
Developments and the benefits thereof are and shall immediately become the sole and absolute property of the Company and its assigns, as works made for hire or otherwise. The term “Development” shall mean any invention, modification,
discovery, design, development, improvement, process, software program, work of authorship, documentation, content, formula, data, technique, know-how, trade secret or intellectual property right whatsoever or any interest therein (whether or not
patentable or registrable under copyright, trademark or similar statutes or subject to analogous protection). I shall promptly disclose to the Company (or any persons designated by it) each such Development. I hereby assign all rights (including,
but not limited to, rights to inventions, patentable subject matter, copyrights and trademarks) I may have or may acquire in the Developments and all benefits and/or rights resulting therefrom to the Company and its assigns without further
compensation and shall communicate, without cost or delay, and without disclosing to others the same, all available information relating thereto (with all necessary plans and models) to the Company. 

(b) Excluded Developments. I represent that the Developments identified in the Appendix, if any, attached hereto comprise all the
Developments that I have made or conceived prior to my Business Relationship with the Company, which Developments are excluded from this Agreement. I understand that it is only necessary to list the title of such Developments and the purpose thereof
but not details of the Development itself. IF THERE ARE ANY SUCH DEVELOPMENTS TO BE EXCLUDED, THE UNDERSIGNED SHOULD INITIAL HERE; OTHERWISE IT WILL BE DEEMED THAT THERE ARE NO SUCH EXCLUSIONS.
            . 
 5. Further Assurances. I shall, during my Business
Relationship and at any time thereafter, at the request and cost of the Company, promptly sign, execute, make and do all such deeds, documents, acts and things as the Company and its duly authorized officers may reasonably require: 

(a) to apply for, obtain, register and vest in the name of the Company alone (unless the Company otherwise directs) patents, copyrights,
trademarks or other analogous protection in any country throughout the world relating to a Development and when so obtained or vested to renew and restore the same; and 

(b) to defend any judicial, opposition or other proceedings in respect of such applications and any judicial, opposition or other proceeding,
petition or application for revocation of any such patent, copyright, trademark or other analogous protection. 

 If the Company is unable, after reasonable effort, to secure my signature on any application for
patent, copyright, trademark or other analogous protection or other documents regarding any legal protection relating to a Development, whether because of my physical or mental incapacity or for any other reason whatsoever, I hereby irrevocably
designate and appoint the Company and its duly authorized officers and agents as my agent and attorney-in-fact, to act for and in my behalf and stead to execute and file any such application or applications or other documents and to do all other
lawfully permitted acts to further the prosecution and issuance of patent, copyright or trademark registrations or any other legal protection thereon with the same legal force and effect as if executed by me. 

6. Non-Competition and Non-Solicitation. 

(a) Acknowledgment. I acknowledge that the Company is engaged in a highly competitive business and that I will have access to
Confidential Information relating to the Company’s business that provides the Company with a competitive advantage that is not generally known by persons not in a Business Relationship with the Company. I also acknowledge that the Company
intends to invest considerable time, effort, and capital in enhancing the value and desirability of the skills of its personnel. Both this investment and my individual compensation, whether in the form of equity compensation or otherwise, reflect
the Company’s expectation of receiving a considerable return from the use of my services and know-how in the future, free from any danger that the Company’s competitors may attempt to induce me to leave the Company and wrongfully gain the
benefit of the Company’s investment and/or Confidential Information. 
 (b) Non-Competition Obligations. During the period of my
Business Relationship with the Company and for two years thereafter (the “Non-Compete Period”), I agree that I will not, directly or indirectly, alone or as a consultant, partner, joint venturer, agent, independent contractor,
officer, director, employee or stockholder of any entity, engage in any business activity which is in competition with the products or services being planned, developed, manufactured, sold or otherwise provided by the Company during the Non-Compete
Period; provided, however, that I may own, solely as a passive investment, not more than three percent (3%) of any class of securities of any corporation that is publicly traded on any national securities exchange in the United
States of America or reported on the National Association of Securities Dealers, Inc.’s Automated Quotation System. 
 (c)
Non-Solicitation Obligations. I further agree that for a period of two (2) years following the period of my Business Relationship with the Company, I (whether as a partner, shareholder, owner, officer, director, employee, principal,
agent, creditor, trustee or consultant of any entity or otherwise) will not, without the prior written consent of the Company, directly or indirectly, (i) induce or attempt to influence any employee or consultant of the Company to leave its
employ, (ii) hire any person who is an employee or consultant of the Company, (iii) aid or agree to aid any competitor, customer or supplier of the Company in any attempt to hire any person who shall have been employed or hired by the
Company within the one-year period preceding such requested aid, or (iv) induce or attempt to influence any person or business entity who was a customer or vendor of the Company to transact business with a competitor of the Company during any
portion of the Non-Compete Period. 

 7. Employment At Will. I understand that this Agreement does not constitute an implied or
written employment contract and that my employment with the Company, if any, is on an “at-will” basis. Accordingly, I understand that either the Company or I may terminate my employment or Business Relationship at any time, for any or no
reason, with or without prior notice. 
 8. Severability. I hereby agree that each provision and the subparts of each provision herein
shall be treated as separate and independent clauses, and the unenforceability of any one clause shall in no way impair the enforceability of any of the other clauses of the Agreement. Moreover, if one or more of the provisions contained in this
Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law, such provision or provisions shall be construed by the appropriate judicial body by limiting or reducing it
or them, so as to be enforceable to the maximum extent , compatible with the applicable law as it shall then appear. I hereby further agree that the language of all parts of this Agreement shall in all cases be construed as a whole according to its
fair meaning and not strictly for or against either of the parties. 
 9. Amendments; Waiver. Any amendment to or modification of this
Agreement, or any waiver of any provision hereof, shall be in writing and signed by the Company. Any waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach of such
provision or any other provision hereof. 
 10. Survival. This Agreement shall be effective as of the date entered below. My
obligations under this Agreement shall survive the termination of my Business Relationship regardless of the manner of such termination and shall be binding upon my heirs, executors, administrators and legal representatives. 

11. Assignment. The Company shall have the right to assign this Agreement to its successors and assigns, and all covenants and
agreements hereunder shall inure to the benefit of and be enforceable by said successors or assigns. I may not assign this Agreement. 
 12.
Representations. 
 (a) I represent that my Business Relationship with the Company and my performance of all of the terms of this
Agreement do not and will not breach any agreement to keep in confidence proprietary information acquired by me in confidence or in trust prior to my Business Relationship with the Company nor any other agreement to which I am a party (including any
non-competition or non-solicitation agreement). I have not entered into, and I shall not enter into, any agreement either written or oral in conflict herewith. 

(b) I agree that any breach of this Agreement by me will cause irreparable damage to the Company and that in the event of such breach the
Company shall have, in addition to any and all remedies of law, the right to an injunction, specific performance or other equitable relief to prevent the violation of my obligations hereunder. The Company may apply for such injunctive relief in any
court of competent jurisdiction without the necessity of posting any bond or other security. 

 13. Governing Law; Forum Selection Clause. This Agreement and any claims arising out of
this Agreement (or any other claims arising out of the relationship between the parties) shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts and shall in all respects be interpreted, enforced and
governed under the internal and domestic laws of such state, without giving effect to the principles of conflicts of laws of such state. Any claims or legal actions by one party against the other shall be commenced and maintained in any state or
federal court located in the Commonwealth of Massachusetts, and I hereby submit to the jurisdiction and venue of any such court. 
 14.
Entire Agreement. This Agreement sets forth the complete, sole and entire agreement between the parties on the subject matter herein and supersedes any and all other agreements, negotiations, discussions, proposals, or understandings, whether
oral or written, previously entered into, discussed or considered by the parties. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the undersigned has executed this Agreement as a sealed instrument as of the
date first above written. 
  

			
	/s/ Donald B Melson
	Signature
	
	Donald B. Melson
	Name:	 	
		
	Date:	 	3/16/13
		
	Address:	 	645 Main St., Boxford, MA 01921

 Accepted and Agreed: 
  

	
	MEVION MEDICAL SYSTEMS INCORPORATED
	
	/s/ Arlene Lukey
	Name: Arlene Lukey
	Title: HR Coordinator

 APPENDIX - TITLE/PURPOSE OF DEVELOPMENTS 

The following is a complete list of all Developments and the purpose of those Developments: 

             No Developments 

             See Below 

Developments and purpose:EX-10.10

 Exhibit 10.10 

EMPLOYMENT AGREEMENT 

This Employment Agreement (“Agreement”) is made as of January 23rd ,2012
(the “Effective Date”) between Mevion Medical Systems, Inc., a Delaware corporation (the “Company”), and Michael Cogswell (the “Executive”). 

WHEREAS, the Company desires to employ Executive and the Executive desires to be employed by the Company beginning on or before
February 6, 2012, unless another date is mutually agreed to by Executive and the Company (the actual first day of employment shall be the “Commencement Date”) on the terms contained herein. 

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 
 1. Position and Duties; No Conflicts. 

(a) The Executive shall serve as the Senior Vice President of Marketing and Sales for the Company. The Executive shall report to, take
direction from and assume such duties and responsibilities as are assigned to him by the Company’s Chief Executive Officer (“CEO”) or such other person designated by the CEO from time to time, provided Executive’s primary duty
shall be to secure sales of the Company’s products. The Executive shall devote his full working time and efforts to the business and affairs of the Company provided Executive is permitted to engage in religious, charitable or other community
activities provided such activities do not interfere with Executive’s duties to the Company. Further, any outside business activities, including directorships, must be disclosed to the Board and may not interfere with the Executive’s
performance of the Executive’s duties to the Company as provided in this Agreement. 
 (b) The Executive hereby represents that he is
not bound by the terms of any agreement with any previous employer or other party to refrain from competing, directly or indirectly, with the business of such previous employer or any other party. Executive further represents that his performance of
all the terms of this Agreement (including Exhibit 1) as an employee of the Company does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by Executive in confidence or in trust prior to
his employment with the Company. Executive will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others. 

(c) Executive shall maintain a home office or executive suite office (the “Place of Employment”) within a 50-milc radius of an
international airport within the 48 contiguous states of the United States of America. 
 2. Compensation and Related Matters. 

(a) Recoverable Draw. The Executive’s annual recoverable draw rate shall be $300,000 per year (or $25,000 per month) (the
“Draw”). The Executive’s draw rate shall be subject to review annually by the CEO, Board, or the Compensation Committee. The annual 

 
recoverable draw in effect at any given time is referred to herein as “Draw.” The Draw shall be payable in a manner that is consistent with the Company’s usual payroll practices
and is subject to repayment in accordance with this Agreement. 
 (b) Commissions. The Executive shall be eligible to earn commissions
pursuant to the Agreement, as made be amended from time to time. This Section 2(b) shall apply from the Commencement Date through the end of FY2012 and shall be amended for each fiscal year after FY2012 at the discretion of the Company. From
the Commencement Date until December 31, 2012, Executive’s Commissions shall be based on the Commission Schedule of Table 1. Commissions shall be accrued based on (i) the Commission amount corresponding to the Sales Price of an order
booked by the Company for a MEVION S250 Proton Therapy System (“US Commission” for facilities in the United States or “x-US Commission” for facilities not in the United States), and (ii) the Commission amount corresponding
to the dollar amount of the associated down-payment received at the time of the order (“Down Payment Commission”). For avoidance of doubt, the Commission amount based on the Sales Price is different for orders booked for US customers and
x-US customers. If the Sales Price or the Down Payment amount falls between values on the schedule the corresponding commission value shall be calculated by pro-rating the commission amounts of the Sales Prices immediately above and below the booked
Sales Price or the commission amounts of the Down Payments immediately above and below the booked down payment respectively. Once an order is “booked” (as determined by the Company in good faith) or a Down Payment is received, a Commission
is accrued, although it is not yet due or payable. Collectively, all accrued Commissions shall be the “Outstanding Commissions.” 
 Table 1.
Commission Schedule 
  

																																									
	 Sales Price ($MM)
	  	 	15	  	  	 	16	  	  	 	17	  	  	 	18	  	  	 	19	  	  	 	20	  	  	 	21	  	  	 	22	  	  	 	23	  	  	 	24	  
	 US Commission ($K)
	  	 	0	  	  	 	0	  	  	 	0	  	  	 	50	  	  	 	75	  	  	 	100	  	  	 	125	  	  	 	150	  	  	 	175	  	  	 	200	  
	 x-US Commission ($K)
	  	 	0	  	  	 	0	  	  	 	0	  	  	 	0	  	  	 	25	  	  	 	50	  	  	 	75	  	  	 	100	  	  	 	125	  	  	 	150	  
											
	 Down Payment ($MM)
	  	 	0	  	  	 	0.5	  	  	 	1	  	  	 	1.5	  	  	 	2	  	  	 	2.5	  	  	 	3	  	  	 	3.5	  	  	 	4	  	  	 	4.5	  
	 Down Payment Commission ($K)
	  	 	0	  	  	 	10	  	  	 	25	  	  	 	44	  	  	 	63	  	  	 	81	  	  	 	100	  	  	 	119	  	  	 	138	  	  	 	156	  

 (c) Payment of Commissions. At the pay period immediately after the Executive’s Outstanding
Commissions exceeds the annual Draw, the Company shall pay the Executive the difference between the then Outstanding Commissions and the annual Draw. Thereafter, the Company shall pay the Executive any additional Outstanding Commissions in each pay
period through the end of 2012. If Executive’s employment is terminated under Sections 3(a), 3(b), 3(d) or 3(e), all Outstanding Commissions that the Executive is eligible to receive beyond the annual Draw per this paragraph shall be paid upon
termination. If the Executive’s employment is terminated under Section 3(c), the Executive shall not be entitled to any additional payments. 

  
 2 

 (d) Equity Grants. The Company shall grant the Executive 80,000 shares of the
Company’s Common Stock in the form of stock options (the “Grant”). The exercise price per share of the Grant shall be based on the “fair market value” of the shares on the date of the Grant. The Grant shall be subject to the
other terms and conditions set forth in the applicable stock option. The Grant shall vest as follows: 
 (i) 50,000 shares of
Common Stock shall be subject to four year vesting with one fourth of such shares to vest after one year and the remaining shares to vest monthly in 36 equal parts over the remaining 36 months; 

(ii) 15,000 shares of Common Stock shall vest upon the Company booking a minimum of five (5) orders for MEVION S250 Proton
Therapy Systems, provided that such vesting shall only occur if (i) at least five orders are booked between the Commencement Date and January 31, 2013; (ii) the average selling price based on all orders booked between the Commencement
Date and January 31, 2013 is greater than $19.6MM, and (iii) the average down-payment based on all orders booked between the Commencement Date and January 31, 2013 is equal to or greater than S2.7MM; 

(iii) 15,000 shares of Common Stock shall vest, upon the Company booking a minimum of nine (9) orders for MEVION S250
Proton Therapy Systems, provided that such vesting shall only occur if (i) at least nine (9) orders are booked in 2013; (ii) the average selling price based on all orders booked in 2013 is greater than S19.6MM and (iii) the
average down-payment based on all orders book in 2013 is equal to or greater than $2.7MM. 
 (iv) For the purposes of
Sections 2(d)(ii) and 2(d)(iii), if the first order booked in the month of January 2013 will fulfill the fifth order of Section 2(d)(ii), it shall be counted for that purpose and it shall not be counted for the required orders to achieve the
nine order requirement of Section 2(d)(iii). 
 (e) Ordinary Expenses. The company shall provide a monthly office allowance up to
$1000.00 per month, to cover office space, office supplies and/or other materials for the use by Executive in connection with his duties performed under this Agreement (“Office Allowance”). The Executive shall also be entitled to receive
reimbursement for all reasonable out-of-pocket expenses incurred by him in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior employees. 

(f) Other Benefits. The Executive shall be entitled to participate in or receive benefits under all of the Company’s employee
benefit plans or programs that generally are made available by the Company to employees of similar rank and tenure, subject to and on a basis consistent with the terms, conditions and overall administration of such plan or arrangement. Nothing
contained in this Agreement shall be construed to create any obligation on the part of the Company to establish any specific plan or program, to maintain the effectiveness of any such plan or program or to allow employees at any particular level to
participate in any such plan or program. 
 (g) Vacation. The Executive shall be entitled to accrue up to twenty (20) paid
vacation days in each year, which shall be accrued ratably beginning on the Commencement Date. In other respects, the Company’s vacation policy, as may be in effect from time to time, shall apply. 

  
 3 

 (h) Life Insurance. The Company shall purchase and maintain for the Executive during
Executive’s employment a Term Life Insurance policy with a death benefit of SIMM payable to the Executive’s designated beneficiary. 

3. Termination. The Executive’s employment hereunder may be terminated without any breach of this Agreement under the following
circumstances: 
 (a) Death. The Executive’s employment hereunder shall terminate upon his death. 

(b) Disability. The Company may terminate the Executive’s employment if the Executive is disabled and unable to perform the
essential functions of the Executive’s then existing position or positions with or without reasonable accommodation. Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law
including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. § 12101 et seq. 

(c) Termination by Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of
this Agreement, “Cause” shall mean: (i) conduct by the Executive constituting an act of misconduct in connection with the performance of the Executive’s duties, including, without limitation, misappropriation of funds or property
of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (ii) the commission by the Executive of (A) any felony; or (B) a misdemeanor
involving moral turpitude, deceit, dishonesty or fraud; (iii) any conduct by the Executive that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries and affiliates; (iv) a
material breach by the Executive of any of the provisions contained in Section 7 of this Agreement including, without limitation, any of the provisions of Exhibit 1, which is incorporated by reference into Section 7; (v) a material
violation by the Executive of any of the Company’s written employment policies or procedures; (vi) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being
instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other
materials in connection with such investigation; or (vii) substantial underperformance by the Executive of the duties assigned to him by the CEO as determined in good faith by the CEO, which substantial underperformance continues for a period
of 30 days after the Executive receives written notice from the CEO identifying the performance failure(s). 
 (d) Termination by the
Company Without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. 
 (e)
Termination by the Executive. The Executive may terminate employment hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has
complied with the “Good Reason Process” (hereinafter defined) following the occurrence of any of the following events: (i) a material diminution in the Executive’s responsibilities, authority or duties; or (ii) the

  
 4 

 
material breach of this Agreement by the Company (each a “Good Reason Condition”). Notwithstanding the foregoing, a suspension of the Executive’s responsibilities, authority and/or
duties for the Company during any portion of a bona fide internal investigation or an investigation by regulatory or law enforcement authorities shall not be a Good Reason Condition. Good Reason Process shall mean that (i) the Executive
reasonably determines in good faith that a Good Reason Condition has occurred; (ii) the Executive notifies the Company in writing of the occurrence of the Good Reason Condition within 60 days of the occurrence of such condition; (iii) the
Executive cooperates in good faith with the Company’s efforts, for a period not less than 20 days following such notice (the “Cure Period”), to remedy the Good Reason Condition; (iv) notwithstanding such efforts, the Good Reason
condition continues to exist; and (v) the Executive terminates employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred.

 (f) Notice of Termination. Except for termination as specified in Section 3(a), any termination of the Executive’s
employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. 

(g) Date of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by death,
the date of death; (ii) if the Executive’s employment is terminated for any other reason, the date on which Notice of Termination is given. 

4. Compensation Upon Termination. 

(a) Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or
provide to the Executive (or to the Executive’s authorized representative or estate) (i) any unpaid expense reimbursements, (ii) any accrued but unused vacation, and (iii) if the Executive’s employment is terminated under
Sections 3(a), 3(b), 3(d) or 3(e), any Outstanding Commissions that exceed the annual Draw (together, the “Accrued Benefit”) on or before the time required by law but in no event more than 30 days after the Executive’s Date of
Termination. In the event the Executive’s employment is terminated pursuant to Section 3(c), the Executive shall be required to repay the portion of the Draw that Executive received for the year in which the Date of Termination occurred
(“Year of Termination”) minus any Outstanding Commission for the Year of Termination. 
 (b) Termination by the Company Without
Cause or by the Executive with Good Reason. If the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or if Executive terminates his employment with the Company for Good Reason as provided in
Section 3(e), then the Company shall, through the Date of Termination, pay the Executive his Accrued Benefit. In addition, subject to the Executive signing and not revoking a separation agreement that includes a general release of claims in
favor of the Company and related persons and entities in a form and manner reasonably satisfactory to the Company (the “Release”): 

  
 5 

 (i) for a period of three (3) months, the Company shall continue to pay the Executive the
Draw at the rate in effect on the Date of Termination (the “Severance Amount”). The Severance Amount shall be paid out in substantially equal installments in accordance with the Company’s regular payroll practices over three
(3) months, beginning on the first payroll date that occurs thirty (30) days after the Date of Termination. Solely for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), each installment
payment is considered a separate payment; 
 (ii) subject to the Executive’s copayment of premium amounts at the active employees’
rate, the Company shall pay the remainder of the premiums for the Executive’s participation in the Company’s group health plans pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”);
provided that the Company’s payment obligation shall cease upon the earlier of three (3) months following the Date of Termination or the expiration of the Executive’s rights under COBRA. As a condition of eligibility for such
payments, the Executive shall promptly respond fully to any reasonable inquiries related to COBRA eligibility; 
 (iii) the options granted
under Section 2(d)(i) shall, on the Date of Termination, vest as to the number of option shares that would otherwise have vested as of the date three (3) months from the Date of Termination and all vested options granted under
Section 2(d) shall not terminate (and Executive may exercise such options) for ninety (90) days following the Date of Termination, except in cases of termination due to death or disability in which case the Executive, and in the case of
death, Executive’s beneficiaries may exercise such vested options for a period of twelve (12) months following such event, but in no event shall the vested options be exercised later than the scheduled expiration date of the options. 

Notwithstanding the foregoing, if the Executive materially breaches any of the provisions contained in Section 7 of this Agreement including, without
limitation, any of the provisions contained in Exhibit 1, which is incorporated by reference into Section 7, in addition to all legal and equitable remedies it may have, the Company shall have the right to terminate or suspend all payments of
the Severance Amount and the Benefit Continuation and such cessation of the Severance Amount payments and Benefit Continuation shall not affect Executive’s continuing post-employment obligations. 

5. Acceleration in Connection with a Change in Control. In connection with a Change in Control all of the Executive’s unvested
stock options as granted in Section 2 (d) (i) shall immediately accelerate and become fully exercisable or nonforfeited. 

For purposes of this Agreement, a “Change in Control” shall mean the (x) consolidation or merger of the Company into or with
any other entity or entities (except a consolidation or merger into a subsidiary or merger in which the Company is the surviving corporation and the holders of the Company voting stock outstanding immediately prior to the transaction constitute the
holders of a majority of the voting stock of the subsidiary or surviving corporation outstanding immediately following the transaction), (y) the sale, transfer, lease or other 

  
 6 

 
disposition by the Company of all or substantially all its assets, or (z) the sale, exchange or transfer by the Company’s stockholders, in a single transaction or series of related
transactions, of capital stock representing a majority of the voting power. 
 6. Section 409A. 

(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the
meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive
becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result
of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation
from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the
six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. 

(b) The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any
provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. The parties agree that this
Agreement may be amended, as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. 

(c) The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation Section 1.409A-l(h). 
 (d) The Company makes no representation or warranty and shall have no liability to the
Executive or any other person or entity if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

7. Confidential Information, Noncompetition and Cooperation. 

(a) Restrictive Covenant. The Executive agrees to comply with the Executive Non-Competition, Non-Solicitation, Confidentiality and
Assignment Agreement attached hereto as Exhibit 1, the terms of which are hereby incorporated by reference into this Agreement. 
 (b)
Litigation and Regulatory Cooperation. During and after the Executive’s employment, provided the Company pays the Executive’s reasonable and documented expenses, the Executive shall cooperate fully with the Company in the defense or
prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the 

  
 7 

 
Company that relate to events or occurrences that transpired while the Executive was employed by the Company. The Executive’s full cooperation in connection with such claims or actions shall
include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive’s employment, the Executive
also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local agency, administrative body or other regulatory authority as any such investigation or review relates to events or occurrences
that transpired while the Executive was employed by the Company. 
 (c) Injunction. The Executive agrees that it would be difficult to
measure any damages caused to the Company that might result from any breach by the Executive of the promises set forth in this Section 7, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, the
Executive agrees that if the Executive breaches, or proposes to breach, any portion of this Agreement, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to
restrain any such breach without showing or proving any actual damage to the Company. 
 8. Consent to Jurisdiction. The parties
hereby agree that the state and federal courts in Massachusetts shall have the exclusive jurisdiction to consider any matters related to this Agreement, including without limitation any claim for violation of this Agreement. With respect to any such
court action, the Executive (i) submits to the jurisdiction of such courts, (ii) consents to service of process, and (iii) waives any other requirement (whether imposed by statute, rule of court or otherwise) with respect to personal
jurisdiction or venue. 
 9. Integration. This Agreement constitutes the entire agreement between the parties with respect to the
subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter. 
 10. Withholding. All
payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. 

11. Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision that is
incorporated herein by reference) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those
as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

12. Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the
Executive’s employment to the extent necessary to effectuate the terms contained herein. 
 13. Waiver. No waiver of any
provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of 

  
 8 

 
any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver
of any subsequent breach. 
 14. Notices. All notices, demands, solicitations of consent or approval, and other communications
hereunder shall be in writing and shall be sufficiently given if personally delivered, transmitted by facsimile, sent by electronic transmission or sent postage prepaid by overnight courier or registered or certified mail, return receipt requested,
addressed as follows: if intended for the Company’s principal office or if intended for the Executive, at the last address the Company has on file for the Executive. Notices shall be deemed to have been given and received: (a) if
personally delivered, at the time of receipt; (b) if transmitted on a business day by electronic transmission with confirmation of receipt or by facsimile with machine-generated confirmation of transmission without notation of error, on the
business day it is sent if sent before 5:00 p.m. local time of the recipient, otherwise the next business day; (c) if mailed, on the second Business Day after it is mailed, and (d) if sent by overnight courier, on the next Business Day
after it is sent. The provisions of this Section 14 shall not prohibit the giving of written notice in any other manner; provided, however, that any such written notice shall be deemed given only when actually received. 

15. Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized
representative of the Company, provided that Section 2(b) shall be amended unilaterally by the Company for each fiscal year during which the Executive is employed by the Company. 

16. Governing Law. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the
Commonwealth of Massachusetts, without giving effect to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be
interpreted and applied by the United States Court of Appeals. 
 17. Counterparts. This Agreement may be executed in any number of
counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. 

18. Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or
otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. 

  
 9 

 IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first
above written. 
  

			
	Mevion Medical Systems, Inc.
		
	By:	 	/s/ Joseph Jachinowski
	
	Name: Joseph K. Jachinowski
	Its: CEO
		
	By:	 	/s/ Michael S. Cogswell
	
	Name: Michael Cogswell
	Address:

  
 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]